Kashi Cereal VS Cheerios
Verdict DROP IT BUY IT
The Reality A class-action lawsuit filed in US District Court for the Southern District of California identified a range of synthetic and artificial ingredients present in products carrying the 'All Natural' or 'Nothing Artificial' label, including pyridoxine hydrochloride, calcium pantothenate, hexane-processed soy ingredients, ascorbic acid, glycerin, and sodium phosphate. Kellogg settled the suit for $5 million in 2014, agreeing to drop the 'All Natural' and 'Nothing Artificial' claims from the affected products and to reformulate or relabel them nationally, with California purchasers eligible for $0.50 per product with proof of purchase. On May 5, 2009, the FDA sent General Mills a formal warning letter finding these specific, quantified claims made Cheerios an unapproved new drug under federal law, since companies are legally barred from quantifying a specific percentage health benefit the way General Mills had. Critically, the underlying science itself wasn't in dispute: Cheerios' general soluble-fiber cholesterol-lowering claim had already been an FDA-authorized qualified health claim for 12 years at that point, and General Mills maintained the clinical study behind the 4% figure was genuinely strong. The issue the FDA flagged was specifically the precise quantification ('4% in 6 weeks'), not the broader, already-approved claim that whole-grain oat soluble fiber can help reduce cholesterol as part of a diet low in saturated fat.
SHORT ANSWER
Kashi Cereal: Kellogg paid $5 million in 2014 to settle a class-action lawsuit and agreed to drop 'All Natural' and 'Nothing Artificial' labeling from Kashi products after plaintiffs identified specific synthetic ingredients, including pyridoxine hydrochloride and hexane-processed soy, actually present in them.
Cheerios: Cheerios' general claim that whole-grain oat soluble fiber can help lower cholesterol is a legitimate, FDA-authorized health claim with real science behind it -- but General Mills' specific 2009 quantified claim ('4% in 6 weeks') crossed into illegal, unapproved drug-claim territory and drew a formal FDA warning letter.